IntegraGen, founded in 2000, is a biotechnology company determined to advance the fields of autism and oncology. On October 28, 2013, the company was proud to reveal the success of a study that can predict the risk of autism in children who are displaying early signs of a developmental delay.
Using 2,500 children with autism and 3,500 controls, the researchers were able to identify over 1,500 genetic variants that are said to be associated with autism. Creators of the ARISk Test, IntegraGen is confident they can use these results to further update the test and permit “physicians to prescribe the test for a broader patient population of children who have early signs of autism but no family history of the disorder.”[i]
Claire Amiet, M.D., Ph.D, Clinical Research Manager at IntegraGen and a practicing child psychiatrist from the Department of Child and Adolescent Psychiatry at Groupe Hospitalier Pitié-Salpêtrière in France comments on the findings,
“We believe these findings may help contribute to an earlier referral of children who are at increased risk of autism, leading to an earlier diagnosis, earlier intervention, and better prognosis.”
The Center for Disease Control estimates that 1 in 88 children are diagnosed with autism, and that on average, children do not receive this diagnosis until they are at least 4-years-old. Receiving an early diagnosis for autism is imperative so the child can begin the necessary therapies. The results of this study are impressive and will surely advance the autism field.
[i] “The Wall Street Journal” IntegraGen announces study results with advanced version of the ARISk test designed to identify risk of autism in broader patient population. 28 Oct 2013. Web. < http://online.wsj.com/article/PR-CO-20131028-907915.html>